MedTrace Logo

Pharmacogenetic-Guided Antidepressant Prescribing in Adolescents With Anxiety and Depression

NCT06853587 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 452

Last updated 2026-05-14

No results posted yet for this study

Summary

This is a parallel arm randomized (1:1) controlled trial. Adolescents aged 12-17 years (n=452) who are starting or changing a selective serotonin reuptake inhibitor (SSRI) for depression and/or anxiety will be randomly allocated to receive 12-weeks of pharmacogenetic-guided antidepressant therapy (experimental intervention) or current prescribing guidelines/recommendations guided therapy (control intervention).

Conditions

  • Anxiety and Depression

Interventions

OTHER

Pharmacogenetic-guided dosing

SSRI dosing based on Clinical Pharmacogenetics Implementation Consortium's SSRI dosing guidelines.

OTHER

Current prescribing guidelines/recommendations

SSRI dosing based on current prescribing guidelines/recommendations

Sponsors & Collaborators

  • University of Calgary

    lead OTHER

Principal Investigators

  • Chad Bousman, PhD · University of Calgary

  • Amanda Newton, PhD · University of Alberta

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-11
Primary Completion
2027-09-30
Completion
2027-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06853587 on ClinicalTrials.gov